目的 观察复方苦参注射液联合XELOX化疗方案治疗术后结直肠癌患者的临床疗效。方法 选择2021年1月—2022年6月在长春市人民医院手术的80例结直肠癌患者，按照治疗方法分为对照组（40例）和治疗组（40例）。对照组采用XELOX化疗方案治疗，第1天将130 mg/m²注射用奥沙利铂混在250 mL葡萄糖注射液中静脉滴注2～6 h，同时口服卡培他滨片，2次/d，每次1 000 mg/m²。治疗组在对照组基础上，从第1天开始将20 mL复方苦参注射液加入250 mL生理盐水中静脉注射，1次/d，连续治疗14 d，间隔7 d。两组均以21 d为1个疗程，持续治疗2个疗程。观察两组患者临床疗效，比较治疗前后两组T淋巴细胞和NK细胞水平，血红蛋白（Hb）、白蛋白（Alb）和转铁蛋白（TRF）指标水平及不良反应情况。结果 治疗后，治疗组总有效率为87.50%，明显高于对照组患者（60.00%，P＜0.05）。治疗后，两组CD3^＋、CD4^＋、CD4^＋/CD8^＋水平和NK细胞水平均高于治疗前，而CD8^＋水平低于治疗前，且治疗组T淋巴细胞和NK细胞水平均明显好于对照组（P＜0.05）。治疗后，两组患者Hb、Alb、TRF高于治疗前（P＜0.05），且治疗组明显高于对照组（P＜0.05）。治疗后，治疗组出现胃肠道反应、肝功能异常、神经毒性和骨髓抑制等并发症的患者数均低于对照组（P＜0.05）。结论 复方苦参注射液联合XELOX化疗方案对术后结直肠癌患者具有较好的疗效，可提高患者免疫功能及营养状况，且安全性高。

Objective To observe the clinical effect of compound matrine injection combined with XELOX chemotherapy in treatment of colorectal cancer. Methods Patients (80 cases) with colorectal cancer in Changchun People’s Hospital from January 2021 to June 2022 were divided into control (40 cases) and treatment (40 cases) group according to the treatment. Patients in the control group were administered with XELOX chemotherapy regimen, 130 mg/m² Oxaliplatin for injection was mixed with 250 mL glucose injection for the 1st day, and they were intravenous dripped for 2 — 6 h, and Capecitabine Tablets were taken orally, twice daily, 1 000 mg/m² each time. Patients in the treatment group were iv administered with Compound Kushen Injection on the basis of the control group for 14 d, then stopped for 7 d, 20 mL added into normal saline 250 mL. 21 days as a course of treatment, and patients in two groups were treated for 2 courses. After treatment, the clinical evaluation was evaluated, and the T-lymphocyte and NK cell levels，the levels of Hb, Alb and TRF, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of patients in the treatment group was 87.50%, which was significantly higher than that in the control group (60.00%, P < 0.05). After treatment, the levels of CD3⁺, CD4⁺, CD4⁺/CD8⁺ and NK cells in two groups were higher than those before treatment, while the level of CD8⁺ was lower than that before treatment, and the levels of T lymphocytes and NK cells in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the indexes of Hb, Alb and TRF in two groups were higher than those before treatment (P < 0.05), and which in the treatment group were significantly higher than those in control group (P < 0.05). After treatment, the patients with complications such as gastrointestinal reaction, abnormal liver function, neurotoxicity and myelosuppression in the treatment group were less than the control group (P < 0.05). Conclusion Compound Kushen Injection combined with XELOX chemotherapy regimen has a good effect on postoperative colorectal cancer patients, which can improve the immune function and nutritional status of patients, and high safety.

R979.1